Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: A meta-analysis

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Zhang, Xunlei ^a   Cao, Chunxiang ^a   Zhang, Qi ^a   Chen, Yi ^b   Gu, Dongying ^a   Shen, Yunzhu ^a   Gong, Yongling ^a   Chen, Jinfei ^a   Tang, Cuiju ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG COMBINATIONS; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; HUMANS; ODDS RATIO; OXONIC ACID; PROPORTIONAL HAZARDS MODELS; PUBLICATION BIAS; TEGAFUR; TREATMENT OUTCOME;

EID: 84894242666     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084230     Document Type: Article

References (41)

1. Desauw C (2010) [Epidemiology and risk factors of colorectal cancer]. Soins: 30-32.
2. Shin A, Kim J, Park S (2011) Gastric cancer epidemiology in Korea. J Gastric Cancer 11: 135-140.
3. Shridhar R, Dombi GW, Finkelstein SE, Meredith KL, Hoffe SE (2011) Improved survival in patients with lymph node-positive gastric cancer who received preoperative radiation: an analysis of the Surveillance, Epidemiology, and End Results database. Cancer 117: 3908-3916.
4. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, et al. (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997. (Pubitemid 46631401)
5. Cunningham D, Okines AF, Ashley S (2010) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 362: 858-859.
6. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, et al. (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221.
7. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, et al. (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20: 666-673.
8. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, et al. (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084-2091. (Pubitemid 41095141)
9. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947. (Pubitemid 30644117)
10. Schoffski P (2004) The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 15: 85-106.
11. (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 16: 301-308.
12. Maehara Y (2003) S-1 in gastric cancer: a comprehensive review. Gastric Cancer 6 Suppl 1: 2-8.
13. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, et al. (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28: 1547-1553.
14. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D (2009) Metaanalysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 20: 1529-1534.
15. Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, et al. (2008) A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 99: 584-590.
16. Kim GM, Jeung HC, Rha SY, Kim HS, Jung I, et al. (2012) A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 48: 518-526.
17. Seol YM, Song MK, Choi YJ, Kim GH, Shin HJ, et al. (2009) Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study. Jpn J Clin Oncol 39: 43-48.
18. Shitara K, Sawaki A, Matsuo K, Kondo C, Takahari D, et al. (2013) A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer. Int J Clin Oncol 18: 539-546.
19. Hong YS, Park YS, Lim HY, Lee J, Kim TW, et al. (2012) S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol 13: 1125-1132.
20. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834. (Pubitemid 28562978)
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
22. Sutton AJ, Song F, Gilbody SM, Abrams KR (2000) Modelling publication bias in meta-analysis: a review. Stat Methods Med Res 9: 421-445. (Pubitemid 32050882)
23. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
24. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
25. Zang DY, Chung I-J, Oh HS, Park KU, Lee KH (2012) Randomized phase II study of oxaliplatin and S-1 (OS) versus oxaliplatin and capecitabine (XELOX) in patients with advanced or recurrent colorectal cancer. J Clin Oncol 2012;595 (Abstract).
26. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, et al. (2007) Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol 25: 965 s(Abstract).
27. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, et al. (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46.
28. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697.
29. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, et al. (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29: 3968-3976.
30. Sakamoto J, Chin K, Kondo K, Kojima H, Terashima M, et al. (2006) Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 17: 231-236.
31. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, et al. (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720. (Pubitemid 28474225)
32. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, et al. (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13: 566-575. (Pubitemid 34461140)
33. Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, et al. (2003) Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 9: 134-142. (Pubitemid 36109725)
34. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, et al. (2005) Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23: 6957-6965.
35. Chuah B, Goh BC, Lee SC, Soong R, Lau F, et al. (2011) Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 102: 478-483.
36. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, et al. (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10: 1063-1069.
37. Yamada Y, Yamamoto S (2009) Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. J Clin Oncol27:15 s (Abstr 4535).
38. Napieralski R, Ott K, Kremer M, Specht K, Vogelsang H, et al. (2005) Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res 11: 3025-3031. (Pubitemid 40525208)
39. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, et al. (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327. (Pubitemid 30226214)
40. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, et al. (2003) Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9: 786-791. (Pubitemid 36182616)
41. Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, et al. (2006) Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24: 4069-4077. (Pubitemid 46622281)